Get the Stockscreener App
0.3258
1.81%
-0.006
After Hours:
.34
0.0142
+4.36%
Io Biotech Inc stock is traded at $0.3258, with a volume of 296.74K.
It is down -1.81% in the last 24 hours and up +1.72% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$0.3318
Open:
$0.32
24h Volume:
296.74K
Relative Volume:
0.03
Market Cap:
$23.44M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.151
EPS:
-2.1574
Net Cash Flow:
$-72.06M
1W Performance:
-9.25%
1M Performance:
+1.72%
6M Performance:
-83.29%
1Y Performance:
-63.80%
1-Day Range:
$0.32
$0.3361
1-Week Range:
$0.306
$0.3627
52-Week Range:
$0.2053
$2.79
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Compare IOBT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.3258 | 23.87M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Io Biotech Inc Stock (IOBT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-08-26 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-30-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-30-25 | Downgrade | TD Cowen | Buy → Hold |
Io Biotech Inc Stock (IOBT) Latest News
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest - Defense World
IOBT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IOBT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Portfolio Update: Is IO Biotech Inc stock a smart retirement pick2025 Support & Resistance & Consistent Profit Trading Strategies - baoquankhu1.vn
IO Biotech receives Nasdaq notice for bid price noncompliance - MSN
Is IO Biotech Inc. stock attractive for ETFs2025 Earnings Surprises & Low Risk Entry Point Tips - mfd.ru
Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ DrugsCollaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech - Yahoo Finance
Layoff Tracker: Concerto Downsizes Amid Pivot to Consumer; Faraday Closes Down - BioSpace
Will IO Biotech Inc. outperform its industry peers2025 Key Lessons & Verified Chart Pattern Signals - mfd.ru
Chart Watch: Will IO Biotech Inc outperform tech stocksBuy Signal & Fast Exit Strategy with Risk Control - baoquankhu1.vn
IOBT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IOBT PE Ratio & Valuation, Is IOBT Overvalued - Intellectia AI
IO Biotech Faces Nasdaq Noncompliance, Potential Delisting Risk - TipRanks
IO Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns IO Biotech (NASDAQ: IOBT) on $50M market value rule - Stock Titan
Here's why IO Biotech, Inc. (IOBT) looks ripe for bottom fishing - MSN
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing - Finviz
Is IO Biotech Inc. a top pick in the sectorJuly 2025 Catalysts & Short-Term High Return Ideas - mfd.ru
Guidance Update: Is IO Biotech Inc in a consolidation phaseJuly 2025 PostEarnings & Safe Capital Growth Tips - baoquankhu1.vn
Fierce Biotech Layoff Tracker 2026: ARPA-H makes cuts; GSK trims R&D team - Fierce Biotech
IO Biotech Provides Corporate Update - marketscreener.com
IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Recommendation of “Reduce” from Analysts - Defense World
IO Biotech (IOBT) launches restructuring, CMO exit and up to $2.6M charges - Stock Titan
IO Biotech hires Raymond James as advisor, cuts workforce By Investing.com - Investing.com Canada
IO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction and Cost-Containment Measures - Quiver Quantitative
Cancer vaccine maker IO Biotech cuts staff, hires Raymond James - Stock Titan
Piper downgrades IO Biotech amid strategic alternatives evaluation - Yahoo Finance
IO Biotech stock tumbles after Piper Sandler downgrades on strategic review By Investing.com - Investing.com South Africa
IO Biotech stock tumbles after Piper Sandler downgrades on strategic review - Investing.com South Africa
Piper Sandler Downgrades IO Biotech (IOBT) to Neutral, Lowers Pr - GuruFocus
Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3 - marketscreener.com
IO Biotech stock rating downgraded by Piper Sandler amid strategic review - Investing.com South Africa
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why - MSN
Aug Decliners: Is IO Biotech Inc a potential multi baggerMarket Growth Report & Entry and Exit Point Strategies - baoquankhu1.vn
IOBT IO Biotech, Inc. (NASDAQ) $0.47 on 22 Jan 2026: active intraday mover for traders - Meyka
IO Biotech’s Future Uncertain As Cylembio Cloud Remains - Citeline News & Insights
IO Biotech Begins Review Of Strategic Options As Cash Runway Narrows - Nasdaq
IO Biotech weighs strategic options months after FDA advises against melanoma vaccine filing - European Biotechnology Magazine
IO Biotech admits defeat | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Listed Danish biotech company fights for survival after FDA rejection and failed capital raising - medwatch.com
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36% - intellectia.ai
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq
IO Biotech stock plummets after company explores strategic alternatives By Investing.com - Investing.com Nigeria
IO Biotech stock plummets after company explores strategic alternatives - Investing.com
IO Biotech announces exploration of strategic alternatives - TipRanks
IO mulls more layoffs months after halving head count in wake of cancer vaccine setback - Fierce Biotech
IO Biotech Explores Strategic Alternatives Amid Cost-Cutting Plans - TipRanks
IO Biotech (IOBT) Explores Strategic Alternatives to Maximize Shareholder Value - Intellectia AI
IO Biotech, Inc. Announces Exploration of Strategic Alternatives - TradingView
IO Biotech to explore strategic alternatives - MSN
IO Biotech Announces Exploration of Strategic Alternatives - The Manila Times
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):